MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$1,248,237
EPS
-$0.08
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
50,918
70,000
-824,319*
-
General and administrative
1,160,573
728,509
1,477,204*
527,902
Asset impairment loss
-
-
100,686.5*
-
Total operating expenses
1,211,491
798,509
753,571.5
527,902
Loss from operations
-1,211,491
-798,509
-753,571.5*
-527,902
Interest income (expense)
6,243
-2,129
-43,879*
8,116
Change in fair value of contingent consideration and derivative financial instruments
-
-
-5,207,782.5*
47,280
Loss before income taxes
-
-
-6,005,233
-472,506
Change in fair value of derivative financial instruments-warrants
-42,989
-10,153
-
-
Net loss
-1,248,237
-810,791
-6,005,233
-472,506
Basic EPS
-0.08
-0.07
-1.137
-0.04
Diluted EPS
-0.08
-0.07
-1.137
-0.04
Basic Average Shares
16,193,404
11,620,317
5,279,686
11,620,317
Diluted Average Shares
16,193,404
11,620,317
5,279,686
11,620,317
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$1,248,237
(-19.73%↓ Y/Y)
Interest income
(expense)
$6,243
(28.30%↑ Y/Y)
Loss from operations
-$1,211,491
(30.59%↑ Y/Y)
Change in fair value of
derivative financial...
-$42,989
Total operating
expenses
$1,211,491
(-30.59%↓ Y/Y)
General and
administrative
$1,160,573
(26.22%↑ Y/Y)
Research and development
$50,918
(-87.97%↓ Y/Y)
Buy us a coffee
Hepion Pharmaceuticals, Inc. (HEPA)
Hepion Pharmaceuticals, Inc. (HEPA)